OTLK
Outlook Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 26 to Jun 2 ▲ 4 days of insider buys: $5.3M by 5 insiders, avg $0.2490
- May 26 ▲ Outlook Therapeutics announced that the FDA granted its Formal Dispu…
- Jul 24 ▲ Outlook Therapeutics announced FDA approval of LYTENAVA (bevacizumab…
- Jul 24 ▲ Outlook Therapeutics received FDA approval for LYTENAVA (bevacizumab…
- Jul 27 ▲ BTIG upgrades
- Jul 29 ▲ 1 insider buy $100.0K at $1.05
- Aug 12 to Aug 14 ▲ 2 days of insider buys: $2.5M by 3 insiders, avg $0.4500
- Aug 13 Offering: Outlook Therapeutics Announces Pricing of $55.0 Million Pu…
- Aug 14 ▼ Outlook Therapeutics reported Q3 FY2026 results with net loss of $20…
- Aug 14 ▼ Outlook Therapeutics priced a $55.0M registered direct offering of 5…
- Aug 14 ▼ Outlook Therapeutics priced a $55M underwritten public offering of 5…
- Aug 31 ▼ Short interest jumps 65.4% to 32.91M
Signal stack
Where each data set points today.
- InsidersBULLISH
7 insiders bought $7.9M at an average $0.6696. No open-market sales. Price is 41% below their cost.
- InstitutionsBULLISH
Q3 2026: 13 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
7 of 10 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.080 → −$0.075 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +9.1% to 35.55M shares. 10.1 days to cover, ≈14.6% of shares.
- TrendDOWNTREND
29% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | DOUBLED | $5.2M |
| MARSHALL WACE, LLP | DOUBLED | $4.6M |
| UBS Group AG | DOUBLED | $1.9M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $984.7K |
| VANGUARD FIDUCIARY TRUST CO | ADD | $613.0K |
| CITIGROUP INC | DOUBLED | $127.1K |
| JANE STREET GROUP, LLC | NEAR_EXIT | $91.0K |
| NewEdge Advisors, LLC | DOUBLED | $34.8K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is below the lowest target. Median implies +910%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 11, 2026 | Ascendiant Capital MAINTAIN | Buy |
| Aug 14, 2026 | BTIG REITERATE | Buy |
| Jul 27, 2026 | HC Wainwright & Co. MAINTAIN | Neutral |
| Jul 27, 2026 | BTIG UPGRADE | Buy |
| Jun 11, 2026 | Ascendiant Capital MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Lundquist Kevin Michael Chief Financial Officer Sep 1, 2026 | AWARD | 500,000 sh |
KENYON LAWRENCE A Chief Financial Officer Aug 14, 2026 | BUY | 101,010 sh |
KENYON LAWRENCE A Chief Financial Officer Aug 14, 2026 | BUY | 101,010 sh |
Jahr Robert Charles Chief Executive Officer Aug 14, 2026 | BUY | 151,515 sh |
Jahr Robert Charles Chief Executive Officer Aug 14, 2026 | BUY | 151,515 sh |
Sukhtian Ghiath M. Director Aug 12, 2026 | BUY | $2.5M |
Sukhtian Ghiath M. Director Aug 12, 2026 | BUY | 2,525,252 sh |
Sukhtian Faisal Ghiath Director Jul 29, 2026 | BUY | $100.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.07 | -$0.08–-$0.07 | -36.4% | $2.2M |
| Next Q | -$0.05 | -$0.08–-$0.01 | +6.7% | $5.3M |
| Current FY | -$0.43 | -$0.45–-$0.42 | +11.8% | $682.7K |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026| Jul 24, 2026 | Volatility Pause | Resumed |
| Jul 24, 2026 | Resumption Scheduled | Resumed |
SecBot reports
28 filings · 9 press releases · 6 bullish · 11 bearish · 2 mixed · 9 neutral- NEUTRAL SC 13GOct 13, 2026
Empery Asset Management, LP filed a Schedule 13G disclosing a passive 8.73% stake in Outlook…
Monitor for any future conversion of this 13G to a 13D, which would signal activist intent. The passive nature and prior filings suggest no near-term catalyst from this holder.
- NEUTRAL PRESS RELEASEOct 6, 2026
Outlook Therapeutics participated in a Virtual Investor segment featuring its new CFO Kevin…
This is a routine corporate update with no new financial data or catalysts. Monitor for the first commercial launch update or first-quarter sales data from the US launch for the first read on…
- NEUTRAL 8-KSep 18, 2026
Outlook Therapeutics announced the U.S. wholesale acquisition cost (WAC) for LYTENAVA at $485 per…
Monitor upcoming quarterly filings for initial LYTENAVA sales volumes and revenue contribution to gauge commercial uptake against the $485/vial WAC.
- BEARISH 8-KAug 14, 2026
Outlook Therapeutics priced a $55.0M registered direct offering of 55,555,556 shares of common…
The stock will likely trade down toward the $0.99 offering price as the market absorbs the new shares. Watch for the stock to settle below the $1.10 warrant exercise price, which would render the…
All OTLK filing & press-release reports (37)
- SC 13G reportOct 13, 2026
- PRESS-RELEASE reportOct 6, 2026
- 8-K reportSep 18, 2026
- 8-K reportAug 14, 2026
- 8-K reportAug 14, 2026
- 424B5 reportAug 14, 2026
- PRESS-RELEASE reportAug 14, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportAug 12, 2026
- 8-K reportJul 24, 2026
- PRESS-RELEASE reportJul 24, 2026
- 8-K reportJul 23, 2026
- EFFECT reportJul 22, 2026
- DEFA14A reportJul 10, 2026
- 8-K reportJun 26, 2026
- 8-K reportJun 16, 2026
- PRESS-RELEASE reportJun 16, 2026
- 8-K reportJun 1, 2026
- CLUSTER reportJun 3, 2026
- CLUSTER reportJun 1, 2026
- DEFA14A reportJun 1, 2026
- 8-K reportMay 29, 2026
- 424B5 reportMay 29, 2026
- 8-K reportMay 28, 2026
- PRESS-RELEASE reportMay 28, 2026
- CLUSTER reportMay 27, 2026
- PRESS-RELEASE reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- PRESS-RELEASE reportApr 23, 2026
- 424B5 reportApr 23, 2026
- 8-K reportApr 21, 2026
- 8-K reportApr 7, 2026
- 424B5 reportMar 24, 2026
- PRESS-RELEASE reportMar 25, 2026
- PRESS-RELEASE reportMar 23, 2026
- 8-K reportMar 11, 2026
- 8-K reportMar 5, 2026